phrykt

INSMED (INSM) revenue: $606M

INSMED reported $606M of revenue for the year ended Dec 31, 2025, up 66.7% from $364M a year earlier.

From INSMED's filings with the SEC · Read the filing · INSM stock page

INSMED revenue by year

$188M2021$245M2022$305M2023$364M2024$606M2025

#1,887 of 3,622 US companies by revenue · See the full ranking

Year endedRevenueChange
Dec 31, 2025$606M+67%
Dec 31, 2024$364M+19%
Dec 31, 2023$305M+24%
Dec 31, 2022$245M+30%
Dec 31, 2021$188M–

Revenue of similar companies

Companies in the same industry as INSMED, by SEC industry code, with the closest revenue. Each name opens the same page for that company.

CompanyRevenue, latest yearYear ended
Kiniksa Pharmaceuticals International$678MDec 31, 2025
Ultragenyx Pharmaceutical$673MDec 31, 2025
Axsome Therapeutics$638MDec 31, 2025
TG Therapeutics$616MDec 31, 2025
Opko Health$607MDec 31, 2025
INSMED$606MDec 31, 2025
HUTCHMED (China)$549MDec 31, 2025

Questions and answers

What is INSMED's revenue?

INSMED reported $606M of revenue for the year ended Dec 31, 2025, up 66.7% from $364M a year earlier.

Numbers as reported in INSMED's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology